Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13. November 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Report Second Quarter 2021 Financial Results
22. Juli 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close...
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
04. Juni 2021 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high...
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
02. Juni 2021 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is...
Travere Therapeutics Announces Proposed Public Offering of Common Stock
10. Februar 2021 16:01 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
12. Januar 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
Travere Therapeutics Provides Corporate Update and 2021 Outlook
11. Januar 2021 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
01. Dezember 2020 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...